At the time of writing, Cytokinetics Inc [CYTK] stock is trading at $49.62, up 40.45%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYTK shares have gain 34.07% over the last week, with a monthly amount glided 35.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on April 24, 2025, and set its price target to $55. On February 07, 2025, Citigroup initiated with a Buy rating and assigned a price target of $86 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $80 on January 22, 2025. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $80 as its price target on November 08, 2024. Goldman downgraded its rating to Neutral for this stock on August 13, 2024, and downed its price target to $60. In a note dated January 24, 2024, UBS downgraded a Neutral rating on this stock and boosted its target price from $61 to $92.
For the past year, the stock price of Cytokinetics Inc fluctuated between $29.31 and $59.39. Currently, Wall Street analysts expect the stock to reach $61 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $49.62 at the most recent close of the market. An investor can expect a potential return of 22.93% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
According to Cytokinetics Inc [NASDAQ:CYTK], the company’s sales were 85.74M for trailing twelve months, which represents an 26714.86% jump. Gross Profit Margin for this corporation currently stands at -2.27% with Operating Profit Margin at -6.38%, Pretax Profit Margin comes in at -7.07%, and Net Profit Margin reading is -7.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is 3.09 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 46.28 points at the first support level, and at 42.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.59, and for the 2nd resistance point, it is at 53.56.
Ratios To Look Out For
It is important to note that Cytokinetics Inc [NASDAQ:CYTK] has a current ratio of 6.76. Further, the Quick Ratio stands at 6.76, while the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 69.25.
Transactions by insiders
Recent insider trading involved Kaye Edward M. MD, Director, that happened on Sep 02 ’25 when 6756.0 shares were sold. Director, ROBERT HARRINGTON completed a deal on Sep 02 ’25 to buy 4300.0 shares. Meanwhile, Director Harrington Robert Arthur sold 2150.0 shares on Sep 02 ’25.
